Berubicin hydrochloride is under clinical development by CNS Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Berubicin hydrochloride’s likelihood of approval (LoA) and phase transition for Recurrent Glioblastoma Multiforme (GBM) took place on 16 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Berubicin hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Berubicin hydrochloride overview
Berubicin hydrochloride (RTA 744) is under development for the treatment of glioblastoma, recurrent glioblastoma multiforme, CNS lymphoma, breast cancer, lung cancer, malignant glioma, pediatric brain tumor, pancreatic cancer, high grade gliomas, ovarian cancer and lymphomas. The drug candidate is an anthracycline derivative. It is a lyophilized drug product administered intravenously. It is a potent inhibitor of topoisomerase II. The drug circumvent ATP-binding cassette transporters(multidrug resistance protein 1, breast cancer resistance protein, P-glycoprotein). It was also under development for the treatment of metastatic breast cancer, brain metastasis, anaplastic astrocytoma, anaplastic mixed oligo-astrocytoma, anaplastic oligodendroglioma, neoplastic meningitis (leptomeningeal carcinomatosis) and malignant glioma.
CNS Pharmaceuticals overview
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specialized in developing novel medicines for brain tumours. It carries out research and development operation in matters related to various cancer treatments and related drugs. The company offers anticancer drug treatment for brain and central nervous system tumors. CNS Pharmaceuticals product portfolio includes Berubicin and WP1244. The company’s products find application in various therapeutic areas such as treatment for glioblastoma, brain tumor and other related concerns. It is also involved in developing treatment for pancreatic and ovarian cancers. The company has obtained patent from Houston Pharmaceuticals as well as collaborated with Reata Pharmaceuticals for developing its pipeline products. CNS Pharmaceuticals is headquartered in Texas, the US
Quick View Berubicin hydrochloride LOA Data
|Highest Development Stage|